Anterior Uveitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Anterior Uveitis - Pipeline Review, H1 2016', provides an overview of the Anterior Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis - The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects - The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anterior Uveitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anterior Uveitis Overview 6 Therapeutics Development 7 Pipeline Products for Anterior Uveitis - Overview 7 Anterior Uveitis - Therapeutics under Development by Companies 8 Anterior Uveitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Anterior Uveitis - Products under Development by Companies 12 Anterior Uveitis - Companies Involved in Therapeutics Development 13 Aciont Inc. 13 Aldeyra Therapeutics, Inc. 14 Delenex Therapeutics AG 15 EyeGate Pharmaceuticals, Inc. 16 Kineta, Inc. 17 Neuroptis Biotech 18 Virogenomics BioDevelopment, Inc. 19 Anterior Uveitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 dalazatide - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 dexamethasone acetate - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 dexamethasone sodium phosphate - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 DLX-105 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 LME-636 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 NOP-3 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NS-2 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Recombinant Peptides to Modulate TCR for Uveitis - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Anterior Uveitis - Recent Pipeline Updates 42 Anterior Uveitis - Dormant Projects 50 Anterior Uveitis - Discontinued Products 51 Anterior Uveitis - Product Development Milestones 52 Featured News & Press Releases 52 Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437 52 Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis 52 May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis 53 Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial 53 Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial 54 Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 54 Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 54 Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences 55 Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 55 Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Anterior Uveitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Anterior Uveitis - Pipeline by Aciont Inc., H1 2016 13 Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 14 Anterior Uveitis - Pipeline by Delenex Therapeutics AG, H1 2016 15 Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 16 Anterior Uveitis - Pipeline by Kineta, Inc., H1 2016 17 Anterior Uveitis - Pipeline by Neuroptis Biotech, H1 2016 18 Anterior Uveitis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Anterior Uveitis Therapeutics - Recent Pipeline Updates, H1 2016 42 Anterior Uveitis - Dormant Projects, H1 2016 50 Anterior Uveitis - Discontinued Products, H1 2016 51
List of Figures
Number of Products under Development for Anterior Uveitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption ratRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.